NRG Administrative Core Abstract The NRG Oncology (NRG) Administrative Core provides the leadership and infrastructure necessary to support the largest portfolio of clinical trials among the adult groups in the NCI National Clinical Trail Network (NCTN), a membership encompassing over 220 main member sites ? including nearly every Lead Academic Participating Site (LAPS) and a robust contribution to the overall management and success of the NCTN. NRG utilizes a highly successful multiple-PI model to provide remarkably capable leadership and scientific oversight, dynamic committee leadership and mentoring, knowledgeable and experienced administrative and operational leadership, and appropriate associated support. NRG, a group formed only four years ago, has leveraged the strengths of its legacy groups to form an integrated, modern clinical trials organization addressing specific populations within the NCTN. It is notable that NRG remained highly productive in all realms even while navigating the merger of the three legacy groups, a testament to the remarkable leadership of NRG and the thoughtful organizational structure put into place. In addition to supporting its own goals, NRG is a highly collaborative member of the NCTN. NRG co-led a number of trials with other groups, championed sixteen studies from other groups, participated in numerous NCI-appointed steering committees, workgroups, and task forces, and led the development of new remote monitoring standards. NRG has the leadership and infrastructure in place to continue to support the clinical trial and membership goals as well as continue to serve as engaged stakeholders in the overall management and success of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180868-06
Application #
9627154
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-16
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Spratt, Daniel E; Dai, Darlene L Y; Den, Robert B et al. (2018) Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol 74:107-114
Chan, John K; Brady, William; Monk, Bradley J et al. (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150:247-252
Ulrich, Connie M; Deshmukh, Snehal; Pugh, Stephanie L et al. (2018) Attrition in NRG Oncology's Radiation-Based Clinical Trials. Int J Radiat Oncol Biol Phys 102:26-33
Konstantinopoulos, Panagiotis A; Brady, William E; Farley, John et al. (2018) Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). Gynecol Oncol 150:9-13
Ingle, James N; Kalari, Krishna R; Wickerham, Donald Lawrence et al. (2018) Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics 28:147-152
Klopp, Ann H; Yeung, Anamaria R; Deshmukh, Snehal et al. (2018) Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 36:2538-2544
Kim, S Rim; Song, Nan; Yothers, Greg et al. (2018) Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). Br J Cancer 118:629-633
Eskander, Ramez N; Kauderer, James; Tewari, Krishnansu S et al. (2018) Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 149:525-530
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Timmerman, Robert D; Hu, Chen; Michalski, Jeff M et al. (2018) Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 4:1287-1288

Showing the most recent 10 out of 357 publications